Intra-Cellular Therapies, Inc. (ITCI)

NASDAQ: ITCI · IEX Real-Time Price · USD
61.32
+1.79 (3.01%)
At close: Jun 2, 2023, 4:00 PM
62.19
+0.87 (1.42%)
After-hours: Jun 2, 2023, 6:36 PM EDT
3.01%
Market Cap 5.88B
Revenue (ttm) 310.62M
Net Income (ttm) -228.19M
Shares Out 95.93M
EPS (ttm) -2.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 661,392
Open 60.09
Previous Close 59.53
Day's Range 59.03 - 61.66
52-Week Range 42.01 - 66.56
Beta 1.14
Analysts n/a
Price Target n/a
Earnings Date May 4, 2023

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as s... [Read more]

Sector Healthcare
CEO Dr. Sharon Mates Ph.D.
Employees 561
Stock Exchange NASDAQ
Ticker Symbol ITCI
Full Company Profile

Financial Performance

In 2022, ITCI's revenue was $250.31 million, an increase of 198.69% compared to the previous year's $83.80 million. Losses were -$256.26 million, -9.81% less than in 2021.

Financial Statements

News

Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...

3 days ago - GlobeNewsWire

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 202...

1 month ago - GlobeNewsWire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...

1 month ago - GlobeNewsWire
}

Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner...

1 month ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner...

1 month ago - GlobeNewsWire

Intra-Cellular's stock jumps on new data for depression drug

Shares of Intra-Cellular Therapies Inc. ITCI, +2.46% jumped about 15% in premarket trading on Tuesday after the company said its experimental treatment for major depressive disorder met the primary en...

2 months ago - Market Watch

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features

Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including:

2 months ago - GlobeNewsWire

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021

3 months ago - GlobeNewsWire
}

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

3 months ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

4 months ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

5 months ago - GlobeNewsWire

Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30% i...

7 months ago - GlobeNewsWire

Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

7 months ago - GlobeNewsWire
}

Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase

10 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Intra-Cellular Therapies, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

10 months ago - PRNewsWire

Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast

NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

10 months ago - GlobeNewsWire

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intr...

1 year ago - Newsfile Corp

Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings

Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33.65 million. Net product revenues of Caplyta were $34...

1 year ago - Benzinga

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

First quarter 2022 results reflect strong CAPLYTA ® (lumateperone) launch in bipolar depression

1 year ago - GlobeNewsWire

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Received FDA approval for CAPLYTA ® (lumateperone) for the treatment of bipolar depression in adults.

1 year ago - GlobeNewsWire

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

1 year ago - GlobeNewsWire

Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

1 year ago - GlobeNewsWire

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

1 year ago - Market Watch

Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

1 year ago - GlobeNewsWire

Intra-Cellular Therapies Prices Public Offering of Common Stock

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv...

1 year ago - GlobeNewsWire